Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 24, 2013 - Issue 5
Submit an article Journal homepage
1,716
Views
36
CrossRef citations to date
0
Altmetric
Psoriasis

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

Machaon BonafedeTruven Health Analytics, Cambridge, MA, USACorrespondence[email protected]
,
Barbara H. JohnsonTruven Health Analytics, Cambridge, MA, USA
,
Kathleen M. FoxStrategic Healthcare Solutions, LLC, Monkton, MD, USA
,
Crystal WatsonAmgen Inc., Thousand Oaks, CA, USA
&
Shravanthi R. GandraAmgen Inc., Thousand Oaks, CA, USA
Pages 369-373 | Received 02 Nov 2012, Accepted 15 Nov 2012, Published online: 21 May 2013

References

  • Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–271.
  • Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
  • Dhir V, Aggarwal A. Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol. 2012; DOI:10.1007/s12016-012-8302-6
  • Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14–ii17.
  • McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum. 1999;42:1080–1086.
  • Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70:i77–i84.
  • Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29:10–15.
  • Ko JM, Qureshi AW. Skin and bone: the pathogenetic relationship between psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2010;145:393–406.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–174.
  • Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70:i2–i36.
  • Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2:817–833.
  • Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not “immediate response” TNF genes. J Allergy Clin Immunol. 2009;124:1022–1010. e1-395.
  • Tan JK, Aphale A, Malaviya R, et al. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc. 2007;12:38–45.
  • Enbrel® (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation, 2011.
  • Humira® (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories, 2011.
  • Thayer S, Watson C, Song R, et al. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ. 2010;13:228–235.
  • Chastek B, Fox KM, Watson C, et al. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24:25–33.
  • Chastek B, Fox KM, Watson C, et al. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther. 2012;29:691–697.
  • Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.